ESMO 2021: TKI treatment breaks for advanced/metastatic kidney cancer – the STAR study
There is increasing interest in using treatment breaks to reduce [...]
Effectiveness of second-line sunitinib after immunotherapy in metastatic kidney cancer
There is very little information on the effectiveness of sunitinib [...]
Biological markers of response for kidney cancer
To date, a reliable biomarker is yet to be discovered [...]
Clinical outcomes of first-line sunitinib followed by immunotherapy
A recent study published in Clinical Genitourinary Cancer has found [...]
Neutrophil-lymphocyte ratio as a prognostic biomarker in high-risk locally advanced kidney cancer
An analysis of the data collected during the S-TRAC study, [...]
Sunitinib re-challenge in patients with metastatic kidney cancer
A study published in Clinical Genitourinary Cancer looks at the [...]
Ilixadencel granted Regenerative Medicine Advanced Therapy by FDA for metastatic kidney cancer
The US Food and Drug Administration (FDA) has designated ilixadencel [...]
Patient-reported outcomes with atezolizumab plus bevacizumab in metastatic kidney cancer
This study describes patient-reported outcomes from the phase 3 IMmotion151 [...]
Targeted therapy dose reduction resulted in better clinical outcomes
A recent post hoc analysis of the results from the [...]
Ilixadencel improves responses and survival in metastatic kidney cancer
Results from a recent phase 2 clinical trial of ilixadencel [...]
